MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Journal of Thoracic Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,243 results · 1 filter active ·
Results by year
20062025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,243 works in the cohort · of 4,299,418page 9 of 25

Labels cover 7 of 1,243 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,243 of 1,243 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

17
citations
affno abstractunlabeled
B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)
Glenwood Goss, David Ferry, Scott A. Laurie, Rafal Wierzbicki, Joyce Thompson, Bonne Biesma +4 more
2007· article· en· Journal of Thoracic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
14
citations
affno abstractunlabeled
A Perspective on the MARS2 Trial
Eric Lim, Isabelle Opitz, Gavitt A. Woodard, Raphael Bueno, Marc de Perrot, Raja M. Flores +3 more
2025· editorial· en· Journal of Thoracic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
14
citations
affno abstractunlabeled
Safety and Resource Utilization by Non-small Cell Lung Cancer Histology: Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaïve Patients with Advanced Non-small Cell Lung Cancer
Silvia Novello, Francisco Pimentel, Jean‐Yves Douillard, Mary O’Brien, Joachim von Pawel, John R. Eckardt +4 more
2010· article· en· Journal of Thoracic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
13
citations

How this was built: Screen · Findings · About